138 related articles for article (PubMed ID: 11012676)
21. Characterization of the 20S proteasome in human glioblastomas.
Piccinini M; Rinaudo MT; Anselmino A; Ramondetti C; Buccinnà B; Fiano V; Ghimenti C; Schiffer D
Anticancer Res; 2005; 25(5):3203-10. PubMed ID: 16101128
[TBL] [Abstract][Full Text] [Related]
22. The effect of the interferon-gamma-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context.
Kuckelkorn U; Ferreira EA; Drung I; Liewer U; Kloetzel PM; Theobald M
Eur J Immunol; 2002 May; 32(5):1368-75. PubMed ID: 11981824
[TBL] [Abstract][Full Text] [Related]
23. Reconstitution of proteasome activator PA28 from isolated subunits: optimal activity is associated with an alpha,beta-heteromultimer.
Kuehn L; Dahlmann B
FEBS Lett; 1996 Sep; 394(2):183-6. PubMed ID: 8843160
[TBL] [Abstract][Full Text] [Related]
24. Relationship of the 20S proteasome and the proteasome activator PA28 to atherosclerosis and intimal hyperplasia in the human vascular system.
Faries PL; Rohan DI; Wyers MC; Marin ML; Hollier LH; Quist WC; LoGerfo FW
Ann Vasc Surg; 2001 Nov; 15(6):628-33. PubMed ID: 11769143
[TBL] [Abstract][Full Text] [Related]
25. The proteasome regulator PA28alpha/beta can enhance antigen presentation without affecting 20S proteasome subunit composition.
Schwarz K; Eggers M; Soza A; Koszinowski UH; Kloetzel PM; Groettrup M
Eur J Immunol; 2000 Dec; 30(12):3672-9. PubMed ID: 11169410
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for the activation of 20S proteasomes by 11S regulators.
Whitby FG; Masters EI; Kramer L; Knowlton JR; Yao Y; Wang CC; Hill CP
Nature; 2000 Nov; 408(6808):115-20. PubMed ID: 11081519
[TBL] [Abstract][Full Text] [Related]
27. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.
McCormack TA; Cruikshank AA; Grenier L; Melandri FD; Nunes SL; Plamondon L; Stein RL; Dick LR
Biochemistry; 1998 May; 37(21):7792-800. PubMed ID: 9601040
[TBL] [Abstract][Full Text] [Related]
28. Molecular dissection of the 11S REG (PA28) proteasome activators.
Li J; Rechsteiner M
Biochimie; 2001; 83(3-4):373-83. PubMed ID: 11295500
[TBL] [Abstract][Full Text] [Related]
29. Proteasome activator PA28 and its interaction with 20 S proteasomes.
Kuehn L; Dahlmann B
Arch Biochem Biophys; 1996 May; 329(1):87-96. PubMed ID: 8619639
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon.
Bose S; Stratford FL; Broadfoot KI; Mason GG; Rivett AJ
Biochem J; 2004 Feb; 378(Pt 1):177-84. PubMed ID: 14583091
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin inhibits proteasome activator expression and proteasome activity.
Wang X; Omura S; Szweda LI; Yang Y; Bérard J; Seminaro J; Wu J
Eur J Immunol; 1997 Nov; 27(11):2781-6. PubMed ID: 9394799
[TBL] [Abstract][Full Text] [Related]
32. PA28, an activator of the 20 S proteasome, is inactivated by proteolytic modification at its carboxyl terminus.
Ma CP; Willy PJ; Slaughter CA; DeMartino GN
J Biol Chem; 1993 Oct; 268(30):22514-9. PubMed ID: 8226760
[TBL] [Abstract][Full Text] [Related]
33. Altered proteasome function and subunit composition in aged muscle.
Husom AD; Peters EA; Kolling EA; Fugere NA; Thompson LV; Ferrington DA
Arch Biochem Biophys; 2004 Jan; 421(1):67-76. PubMed ID: 14678786
[TBL] [Abstract][Full Text] [Related]
34. Nucleotide sequence analysis of the approximately 35-kb segment containing interferon-gamma-inducible mouse proteasome activator genes.
Yawata M; Murata S; Tanaka K; Ishigatsubo Y; Kasahara M
Immunogenetics; 2001 Mar; 53(2):119-29. PubMed ID: 11345588
[TBL] [Abstract][Full Text] [Related]
35. Structure of the proteasome activator REGalpha (PA28alpha).
Knowlton JR; Johnston SC; Whitby FG; Realini C; Zhang Z; Rechsteiner M; Hill CP
Nature; 1997 Dec; 390(6660):639-43. PubMed ID: 9403698
[TBL] [Abstract][Full Text] [Related]
36. Alteration of 20S proteasome-subtypes and proteasome activator PA28 in skeletal muscle of rat after induction of diabetes mellitus.
Merforth S; Kuehn L; Osmers A; Dahlmann B
Int J Biochem Cell Biol; 2003 May; 35(5):740-8. PubMed ID: 12672465
[TBL] [Abstract][Full Text] [Related]
37. Human platelet 20S proteasome: inhibition of its chymotrypsin-like activity and identification of the proteasome activator PA28. A preliminary report.
Ostrowska H; Ostrowska JK; Worowski K; Radziwon P
Platelets; 2003 May; 14(3):151-7. PubMed ID: 12850839
[TBL] [Abstract][Full Text] [Related]
38. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain).
Ma CP; Slaughter CA; DeMartino GN
J Biol Chem; 1992 May; 267(15):10515-23. PubMed ID: 1587832
[TBL] [Abstract][Full Text] [Related]
39. [Advance in the study on the proteasome activator PA28].
Murata S; Chiba T
Tanpakushitsu Kakusan Koso; 2000 Aug; 45(11):1832-40. PubMed ID: 10936967
[No Abstract] [Full Text] [Related]
40. MEKK3 interacts with the PA28 gamma regulatory subunit of the proteasome.
Hagemann C; Patel R; Blank JL
Biochem J; 2003 Jul; 373(Pt 1):71-9. PubMed ID: 12650640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
